Intervention: Pyronaridine
Trial phase: Phase 1
ATC code: P01BF06
SMILES: COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: 14C-labeled Pyronaridine: Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
Eligibility criteria:
Inclusion Criteria:

Male subjects between the ages of 40 and 55 years with a body weight between 60 and 90 kg and a body mass index calculated using Quetelet's Index - weight (kg)/height2 (m2) between 18.5 - 30.0
Signed and dated written informed consent form (ICF) before undergoing any study related activities, including discontinuation of any prohibited medications
Medically normal subjects with no significant abnormal findings at the screening physical examination as evaluated by the investigator
Strictly normal values of ALT, AST and bilirubin and normal or abnormal and clinically insignificant results (if agreed by the Investigator and the Sponsor on a case by case evaluation) of the other blood and urine laboratory parameters at screening

All sexually active male subjects and their partners are willing to undergo contraception as follows:

All male subjects, including those who are sterilised (i.e., vasectomy), should use a condom. Their female partner must also use at least 1 of the medically acceptable forms of contraceptives listed below. Male subjects must not donate sperm or have unprotected sex during the study and until 87 days after taking the dose of investigational product.

Medically acceptable contraceptives for this study are:

Condoms in addition to:

Intrauterine devices
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring)
Diaphragms with spermicidal cream or gel
Cervical cap with spermicidal cream or gel
Spermicidal foam
The ability to understand the requirements of the study and willingness to comply with all study procedures

Exclusion Criteria:

Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, acute QTc interval greater or equal to 450 mseconds), respiratory (including active tuberculosis), hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric or other clinical abnormality
Known history of hypersensitivity, allergic or adverse reactions to Pyronaridine
Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab)
Seropositive HIV antibody
Previous participation in any clinical study with Pyramax
Presence or recent history (last two years) of tobacco abuse (≥10 cigarettes/day)
Known or suspected alcohol abuse or illicit drug use in the last 10 years before the study start or positive findings on urine drug screen
Intake of grapefruit and grapefruit juice alcoholic beverages or caffeine-containing food or beverages, such as coffee, tea, chocolate, or cola, 48 hours before study drug administration
Use of over-the-counter (OTC) medications, including vitamins, analgesics, or antacids, 1 week before the study start
Use of prescription medications 14 days before the study start or required chronic use of any prescription medication
Use of enzyme-altering agents (e.g., barbiturates, phenothiazines, cimetidine, etc.) within 30 days or 5 half lives, whichever the longer, before the study start
Plasma donation 1 month before the study start
Blood donation of 450 mL or more in the last 3 months before the study start
Participation in other clinical trials during the previous month in which an investigational drug or a commercially available drug was tested
Exposure to artificial ionizing radiation in the last 12 months (e.g., x-ray investigation, isotope studies)